Literature DB >> 9068727

High incidence of porokeratosis in renal transplant recipients.

P Herranz1, A Pizarro, R De Lucas, M G Robayna, F A Rubio, A Sanz, F Contreras, M Casado.   

Abstract

Immunosuppression is a well-documented precipitant of porokeratosis (PK). However, PK is not considered among the most common cutaneous disorders in immunosuppressed patients. We studied prospectively a series of 103 renal transplant patients and found 11 cases (10.68%) of PK. Our series represents the highest incidence of PK in transplant patients reported so far. Our findings suggest that PK in transplant recipients may be more frequent than previously thought.

Entities:  

Mesh:

Year:  1997        PMID: 9068727

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  5 in total

1.  Acute onset disseminated superficial porokeratosis associated with exacerbation of diabetes mellitus due to development of anti-insulin antibodies.

Authors:  Motonobu Nakamura; Shoko Fukamachi; Yoshiki Tokura
Journal:  Dermatoendocrinol       Date:  2010-01

2.  Atypical porokeratosis developing following bone marrow transplantation in a patient with myelodysplastic syndrome.

Authors:  Sang Hee Cha; Hyun Jeong Park; Jun Young Lee; Baik Kee Cho
Journal:  Ann Dermatol       Date:  2010-05-18       Impact factor: 1.444

3.  Clinical Study of Porokeratosis Associated with Immunosuppressive Therapy in Renal Transplant Recipients.

Authors:  Ye Won Han; Yeon Jeong Kim; Hyung Ok Kim; Young Min Park
Journal:  Ann Dermatol       Date:  2008-12-31       Impact factor: 1.444

4.  Three-dimensional aspects of superficial disseminated porokeratosis with scanning electron microscopy.

Authors:  Hiram Larangeira de Almeida; Luciana Boff de Abreu; Greice Rampon; Ricardo Marques e Silva; Nara Moreira Rocha
Journal:  An Bras Dermatol       Date:  2014 Nov-Dec       Impact factor: 1.896

5.  Clinical analysis and etiology of porokeratosis.

Authors:  Chao-Ying Gu; Cheng-Feng Zhang; Lian-Jun Chen; Lei-Hong Xiang; Zhi-Zhong Zheng
Journal:  Exp Ther Med       Date:  2014-06-24       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.